lunes, 1 de octubre de 2018

Pharma tries to cash in on migraine market by making new drugs free, for now

Pharma tries to cash in on migraine market by making new drugs free, for now

The Readout

Here’s one way to slash (migraine) drug prices

The race to own the migraine space is in such a dead heat that drug companies are employing a rather unusual pricing strategy to edge ahead of one another: They're giving away their drugs for free. 
The latest to try this tactic is Eli Lilly, whose drug was just approved and is virtually identical to offerings from Teva Pharmaceutical and Amgen/Novartis. It's aiming to build up brand loyalty by offering its drug for no charge to patients with private insurance. The program allows patients to receive the drug, free and clear, for up to 12 months. 
Teva is also offering up its migraine treatment for free through the end of 2019, as is the Amgen/Novartis partnership.

No hay comentarios:

Publicar un comentario